3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Interventions
pembrolizumab
70
Nivolumab
47
Ipilimumab
27
Specimen Handling
15
Magnetic Resonance Spectroscopy
15
trametinib
14
Biopsy
13
dabrafenib
11
cemiplimab
11
avelumab
11
Cyclophosphamide
11
binimetinib
10
Radiotherapy
9
CTLA-4 Antigen
9
fludarabine
8
encorafenib
7
atezolizumab
7
Radiosurgery
7
Immunoglobulin G
7
Disulfides
7
Cisplatin
7
fludarabine phosphate
6
durvalumab
6
tislelizumab
5
relatlimab
5
lenvatinib
5
dostarlimab
5
Pemetrexed
5
Paclitaxel
5
Introns
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Tumor Necrosis Factor-alpha
×
Dermatologic
×
Clear all
NCT05222932
2025-08-07
AVENTIL
TILT Biotherapeutics Ltd.
Phase 1
Active not recruiting
15 enrolled